BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Cord Blood

Stem Cell Therapy in India – ReeLabs into Diabetes Clinical Trial

By Leave a Comment

Stem cell therapy in India is emerging as a new modality within the healthcare system. The progress is supported by numerous innovators within the country. One company forging the way is ReeLabs, a leading stem cell bank in India that is supporting the collection and storage of stem cells, as well as the development of novel stem cell therapeutics.

Diabetes Mellitus in India

According to the World Health Organization (WHO), diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period.  Diabetes mellitus is one of the most common diseases globally.

In India, the prevalence of diabetes is rising, predominantly related to factors such as genetic factors, stress, diet, obesity, lack of meaningful exercise and lifestyle related issues. [Read more…]

Celularity Acquires CariCord, Adds Biosourcing Assets, Establishes Relationship with ClinImmune Labs

By Leave a Comment

WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]

FamiCord Acquires the Largest Stem Cell Bank in Portugal for $16.5M

By

FamiCord announced that it is acquiring Stemlab, positioning it to control the largest cord blood bank in Portugal. To execute the transaction, Polski Bank Komórek Macierzystych S.A. (better known as the Polish Stem Cell Bank or PBKM), a leading company of the global Famicord Group, is acquiring a controlling interest in Stemlab. It will be acquiring 95.6% of the company stock for a purchase price of $16.5M. [Read more…]

Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?

By

Gamida CellGamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.

NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]

Cord Blood Banking – Present and Future Outlook

By

Cord blood banking is defined as the collection and storage of stem cells present within the umbilical cord blood of a newborn for future medical use. Umbilical cord blood is rich in a type of stem cell known as a hematopoietic stem cell (HSC). A large market for the storage of these cells has come into existence over the past 30 years, with public and private cord blood banks now present in all major healthcare markets worldwide. [Read more…]

BioInformant's World-Class Clients